Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Ph+ CML-CP with Suboptimal Response to Imatinib
NCT00644878Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Oct 2008; status: terminated.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00644878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00644878.